Track topics on Twitter Track topics that are important to you
Edison Investment Research - Pharmaceuticals & healthcare - Paion: Paion achieved a major milestone in April when partner Cosmo filed for approval of remimazolam in procedural sedation (PS) in the US. This adds to filings in Q418 by partners for general anaesthesia (GA) in Japan and for PS in China. Remimazolam is an ultra-short-acting sedative/anaesthetic that combines the best features of propofol and midazolam. We expect its rapid onset and offset of action combined with a favourable cardio-respiratory safety profile to drive market uptake, if approved. Paion intends to self-commercialise remimazolam for GA and PS in select countries in Europe if it gains approval. Additional partners are seeking approvals in other territories. We increase our valuation to €317m or €4.96 per share.
Original Article: Paion (PA8) - Filed for approval in US, Europe and ChinaNEXT ARTICLE
BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...